A New Step Forward
Addressing the challenge of diabetic macular edema with ILUVIEN®: views from the Expert User Group Meeting in Rome, November 17, 2018
sponsored by Alimera
Diabetic macular edema (DME) is one of the main causes of blindness globally. To address this challenge, we must have access to the best tools available – and match them to appropriate patients. One such tool is ILUVIEN® (fluocinolone acetonide intravitreal implant), indicated for the treatment of vision impairment associated with chronic diabetic macular oedema, considered insufficiently responsive to available therapies (i.e. DME that persists or recurs despite treatment). A recent conference in Rome (ILUVIEN Medical Expert User Group Meeting - an Alimera Sciences promotional meeting) on November 17, 2018 gathered international experts to discuss best practice and real-world experience with this sustained-release steroid implant.
Enjoy our FREE content!
Log in or register to gain full unlimited access to all content on the The Ophthalmologist site. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine